Stable COPD: inhalers, rehabilitation and oxygen

01Purpose and principlesWhat the treatment does and how it fits into care.

Stable COPD treatment targets symptoms, activity, exacerbations and survival-relevant hypoxaemia using different interventions. Bronchodilators reduce dynamic hyperinflation, pulmonary rehabilitation reverses deconditioning and teaches self-management, and ICS/biologic therapy is concentrated in exacerbation-prone, steroid-responsive disease.

Inhaler escalation should be a therapeutic trial with a stated endpoint. Persistent breathlessness despite objectively effective bronchodilation should prompt rehabilitation and a search for heart failure, anaemia, obesity, anxiety, sleep apnoea or pulmonary vascular disease—not automatic polypharmacy.

Oxygen is a specialist physiological treatment. Ambulatory oxygen may help selected people who desaturate and demonstrate benefit, but routine short-burst oxygen for non-hypoxaemic breathlessness does not substitute for rehabilitation or symptom-directed care.

Key points

Treat tobacco dependence, physical deconditioning, vaccination needs, nutrition and comorbidity alongside inhalers; medication alone is not comprehensive COPD care.
Use a short-acting bronchodilator when needed initially. If breathlessness or exacerbations persist without asthmatic/steroid-responsive features, offer LABA+LAMA.
If asthmatic features suggest steroid responsiveness, consider LABA+ICS; review pneumonia and systemic ICS risk and never use ICS monotherapy for COPD.
For persistent disabling symptoms or exacerbations on dual therapy, consider triple LABA+LAMA+ICS according to phenotype and trial response; review and revert if a symptom-led trial gives no benefit.
Choose one device the patient can and will use, demonstrate technique, minimise duplicate drug classes and prescribe the exact brand/dose.
Offer pulmonary rehabilitation to functionally limited people, generally MRC dyspnoea grade 3 or more, and after recent hospitalisation when appropriate.
Consider mucolytic therapy for chronic productive cough and continue only if symptoms improve; do not use cough suppressants routinely in stable COPD.
LTOT is for confirmed stable hypoxaemia after specialist ABG assessment: PaO2 at or below 7.3 kPa, or 7.3-8.0 kPa with polycythaemia, peripheral oedema or pulmonary hypertension.
LTOT benefit requires at least 15 hours/day. It is not prescribed simply for breathlessness with normal oxygenation, and smoking/fire risk must be assessed.
Since March 2026, NICE allows specialist add-on dupilumab for uncontrolled COPD with eosinophils at least 0.3 x10^9/L despite triple therapy, or LABA+LAMA when ICS is inappropriate; assess response at 12 months.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Breathlessness-predominant disease

Persistent activity limitation despite short-acting relief, often from obstruction/hyperinflation plus deconditioning. LABA+LAMA and pulmonary rehabilitation are central after technique and alternatives are reviewed.

Exacerbation-prone disease

Repeated steroid/antibiotic-treated attacks or admissions. Confirm these are COPD exacerbations, optimise dual bronchodilation and consider ICS/triple therapy, eosinophilic advanced therapy, bronchiectasis or prophylactic specialist options.

Steroid-responsive features

Secure asthma/atopy, marked FEV1 variability or higher eosinophils increases the expected ICS benefit. Balance against pneumonia, thrush, bruising and systemic steroid burden.

Chronic hypoxaemiaRed flag

Stable SpO2 at or below 92%, cyanosis, polycythaemia, pulmonary hypertension, peripheral oedema or very severe obstruction should prompt formal ABG-based LTOT assessment, not an oxygen prescription from oximetry alone.

Advanced eosinophilic COPD

Eosinophils at least 0.3 x10^9/L plus at least 1 severe or 2 moderate exacerbations in 12 months despite triple therapy, or LABA+LAMA if ICS unsuitable, fits NICE TA1142's clinical definition for considering dupilumab.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Symptom, MRC and exacerbation reviewFirst step
Why
Choose treatment target and measure benefit.
Interpretation and limitations
Record CAT/functional impact, MRC grade, rescue use, admissions and steroid/antibiotic courses; distinguish daily breathlessness from exacerbation risk.
02
Observed inhaler technique and inspiratory/device assessment
Why
Ensure the prescribed dose can be delivered.
Interpretation and limitations
Match DPI, pMDI/spacer or soft-mist device to inspiratory flow, dexterity and cognition; simplify to one device family where possible and check adherence/counters.
03
Blood eosinophils and asthma history
Why
Estimate corticosteroid/biologic-responsive phenotype.
Interpretation and limitations
Use repeated/historical counts and exacerbations. Eosinophils ≥0.3 x10^9/L are the TA1142 biomarker threshold for dupilumab but do not alone mandate treatment.
04
ABGs while stable on two occasions
Why
Confirm LTOT eligibility and hypercapnia.
Interpretation and limitations
Assess after optimal treatment when stable. PaO2 ≤7.3 kPa, or 7.3-8.0 with polycythaemia, oedema or pulmonary hypertension, supports LTOT; specialist titration and safety assessment follow.
05
Exercise test with oximetry when ambulatory oxygen is considered
Why
Demonstrate exertional desaturation and objective benefit.
Interpretation and limitations
Specialist testing assesses correction of desaturation and improvement in exercise capacity/dyspnoea, then determines flow; desaturation alone without benefit is not sufficient.
06
Targeted CT, sputum culture and cardiac/sleep assessment
Why
Find treatable drivers of persistent symptoms or attacks.
Interpretation and limitations
Bronchiectasis, chronic infection, heart failure, OSA/obesity hypoventilation and cancer change the plan; investigate from clues rather than treating every episode as COPD alone.

04Treatment approachPreparation, options, escalation and aftercare.

01InhalersNICE stable inhaler sequenceFirst stepPersistent breathlessness or exacerbations after short-acting therapy and non-pharmacological care.

1Check diagnosis, smoking treatment, technique/adherence and offer pulmonary rehabilitation. Keep SABA or SAMA as-needed initially; stop regular SAMA when a LAMA begins.
2Without asthmatic/steroid-responsive features, offer LABA+LAMA. With such features, consider LABA+ICS, explaining ICS benefits and pneumonia risk.
3If on LABA+LAMA with quality-of-life-limiting daily symptoms, consider a 3-month triple-therapy trial and revert if no improvement. If severe or 2 moderate exacerbations/year occur, offer triple therapy.
4If on LABA+ICS with persistent symptoms or exacerbations, offer LAMA to make triple therapy. Reconcile drugs/device and review response/harms after every change.

02RehabilitationRestore function, not only FEV1MRC dyspnoea grade 3 or more, functional limitation or recovery after admission.

1Offer a multidisciplinary pulmonary-rehabilitation programme with individualised aerobic/strength exercise, education, self-management and nutrition/psychological support.
2Optimise bronchodilator and oxygen needs enough to participate, but do not wait for perfect symptoms. Arrange transport/access adaptations and a home component when needed.
3Measure baseline and completion exercise capacity, breathlessness and quality of life; support ongoing physical activity after the supervised course.

03OxygenFormal LTOT pathwayStable SpO2 ≤92%, very severe obstruction, cyanosis, polycythaemia, oedema or pulmonary hypertension.

1Optimise COPD treatment and assess when stable. Obtain ABGs on 2 occasions at least 3 weeks apart through a specialist oxygen service.
2Offer LTOT for PaO2 ≤7.3 kPa, or 7.3-8.0 kPa with secondary polycythaemia, peripheral oedema or pulmonary hypertension. Prescribe enough for at least 15 hours/day and titrate to the service target.
3Complete smoking/vaping and household fire-risk assessment, provide equipment education and review at least annually with oximetry and adherence. Refer hypercapnic/acidotic patients for long-term NIV consideration.

04Refractory attacksBeyond triple therapyCorrectly diagnosed COPD with attacks despite optimised inhalers, rehabilitation and self-management.

1Recheck inhaler use and look for bronchiectasis, chronic infection, heart failure and ongoing exposure; obtain eosinophil history and specialist respiratory review.
2For severe COPD with chronic bronchitis and frequent exacerbations despite triple therapy, consider roflumilast under NICE TA461/specialist care. Selected non-smokers with sputum may be considered for prophylactic azithromycin after ECG, LFT and hearing review.
3Under NICE TA1142, consider dupilumab if eosinophils ≥0.3 x10^9/L and uncontrolled disease (≥1 severe or ≥2 moderate attacks/12 months) despite triple, or LABA+LAMA if ICS inappropriate; assess response at 12 months and stop if the NICE response rule is not met.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Dual long-acting bronchodilation for persistent symptoms without steroid-responsive features.

Tiotropium/olodaterol LABA+LAMA (example)

5 micrograms tiotropium plus 5 micrograms olodaterol inhaled once daily as 2 puffs of Respimat 2.5/2.5 micrograms.

Not a reliever. Check renal function/antimuscarinic effects, glaucoma/urinary retention, tachyarrhythmia and device technique; avoid duplicate LABA/LAMA.

Single-inhaler triple therapy for selected symptomatic/exacerbation-prone COPD after dual therapy.

Beclometasone/formoterol/glycopyrronium triple inhaler (example)

Trimbow 87/5/9 micrograms: 2 inhalations twice daily; maximum 2 inhalations twice daily.

Rinse mouth; monitor pneumonia, thrush, bruising and systemic ICS effects. Confirm indication and response; this example is not interchangeable with other strengths/devices.

Trial for chronic productive cough with troublesome sputum; continue only with symptomatic benefit.

Carbocisteine

Initially 750 mg orally three times daily (2.25 g/day), reducing to 1.5 g/day in divided doses when a satisfactory response is obtained.

Dyspepsia and GI bleeding risk; use caution with active peptic ulceration. It does not replace airway clearance or investigation of bronchiectasis/infection.

Specialist add-on under NICE TA461 for severe COPD with chronic bronchitis and frequent exacerbations despite triple therapy.

Roflumilast

250 micrograms orally once daily for the first 28 days, then increase to the maintenance dose of 500 micrograms once daily. The 250-microgram dose is only a tolerability starter dose, not a maintenance dose.

Diarrhoea, nausea, weight loss, insomnia and psychiatric effects; avoid in moderate/severe liver impairment and monitor weight/mood. Not an acute bronchodilator.

Specialist add-on for uncontrolled eosinophilic COPD meeting TA1142 criteria.

Dupilumab

300 mg subcutaneously every 2 weeks for COPD; no loading dose is specified for the COPD indication. Assess response at 12 months under NICE TA1142.

Check exact eligibility and commissioning; conjunctivitis, injection reactions and eosinophilic complications can occur. Stop at 12 months if severe attacks are higher, or unchanged with more moderate attacks, versus the prior year.

Improves survival in eligible stable severe chronic hypoxaemia.

Long-term oxygen therapy

Specialist-prescribed flow titrated by ABG/oximetry and used at least 15 hours/day; flow is individual, not a universal litre-per-minute dose.

Fire/explosion risk with smoking or naked flames; hypercapnia requires assessment. Do not prescribe solely for non-hypoxaemic breathlessness.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Reassess symptoms, MRC/CAT, rescue use and attacks after each inhaler change; for symptom-led triple therapy use an explicit 3-month benefit trial.
Watch inhaler technique, adherence and duplicate classes at every review; record the exact brand and delivered dose.
Monitor ICS users for pneumonia, thrush, bruising and cumulative steroid effects; review whether the phenotype and attacks still justify ICS.
LTOT users need at least annual specialist review with oximetry, adherence, equipment and smoking/fire safety; reassess after clinical change.
For roflumilast monitor weight, GI and psychiatric effects; for macrolides monitor ECG/QT, hearing, LFTs and resistance; for dupilumab assess the 12-month NICE response rule.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Pulmonary rehabilitation is core treatment

It improves exercise capacity, breathlessness and quality of life despite little change in FEV1; its mechanism addresses deconditioning that inhalers cannot.

ICS is phenotype-weighted

Benefit is larger when exacerbations and eosinophilic/asthmatic features are present; pneumonia and systemic exposure matter when benefit is uncertain.

Oxygen treats hypoxaemia, not the sensation alone

Breathlessness with normal oxygenation responds better to rehabilitation, breathing strategies and cause-specific care than indiscriminate oxygen.

Single inhaler can reduce error

A suitable combined device can simplify treatment, but only if the patient can generate the required inspiratory pattern and understands the schedule.

2026 biologic criteria are explicit

Dupilumab eligibility combines biomarker, exacerbation burden and optimised background therapy, with a defined stop review; eosinophils alone are not enough.

08Common pitfallsFrequent interpretation and management errors.

01
Escalating inhalers for breathlessness caused mainly by heart failure, anaemia or deconditioning.
02
Adding ICS without exacerbation/steroid-responsive rationale or reviewing pneumonia risk.
03
Leaving SAMA prescribed regularly after starting a LAMA.
04
Prescribing oxygen from one low oximeter reading during an exacerbation rather than stable ABG assessment.
05
Calling pulmonary rehabilitation optional lifestyle advice rather than active treatment.
06
Starting advanced therapy without confirming adherence, device use, phenotype and exacerbation count.